California Stem Cell (CSC) and Stemina Biomarker Discovery have announced that the study using CSC’s 96-well CardioPlate containing high purity human embryonic stem cell (hESC)-derived cardiomyocyte progenitor cells,
Teijin, a fine chemical company, has announced that it has begun producing its proprietary heat-resistant bioplastic BIOFRONT at a demonstration plant in Matsuyama, Ehime Prefecture. The plant was
Dey has settled a lawsuit brought against it and other companies by the State of Utah in October 2005 pertaining to Medicaid reimbursements paid by the state to
INEOS NOVA is planing to close the polystyrene (PS) plant at Breda, Netherlands. The plant has a capacity of 90,000 tonne/year with 50 employees. The company said that
Arkema has announced the construction of a carbon nanotube (CNT) pilot production plant at its Mont site (France, Pyrenees-Atlantiques). The 400ton/year plant, scheduled for startup in the beginning
Wound Management Technologies has completed the acquisition of BioPharma Management Technologies, a privately held biotechnology company with a platform of proprietary and patented technologies for topical pain management
The Wellcome Trust and Merck & Co. have announced the creation of the MSD Wellcome Trust Hilleman Laboratories, a not-for-profit research and development joint venture to focus on
imaGenes will provide service offerings with BioTrove’s OpenArray Platform, a nanoliter Real-Time qPCR, allowing for about 9,000 assays simultaneously. Reportedly, OpenArray produces faster results, allowing gene expression profiling,
InVitria has launched Optiferrin, a high performance, well-defined and animal-free recombinant transferrin for use in mammalian cell culture. Optiferrin is a cell culture supplement which supports cell growth
APP Pharmaceuticals, a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals, has received approval from the FDA to market Deferoxamine Mesylate for Injection, USP, in two dosage strengths. Deferoxamine
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.